Upgrade to SI Premium - Free Trial

BioMarin Pharma's (BMRN) Pegvaliase Phase 3 PRISM-2 Met Primary Endpoint

March 21, 2016 6:11 AM
BioMarin (Nasdaq: BMRN) announced that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments

Next Articles